-+ 0.00%
-+ 0.00%
-+ 0.00%

Brookline Capital Upgrades Verrica Pharmaceuticals to Buy, Announces $17 Price Target

Benzinga·12/18/2025 12:39:35
Listen to the news
Brookline Capital analyst Kemp Dolliver upgrades Verrica Pharmaceuticals (NASDAQ:VRCA) from Hold to Buy and announces $17 price target.